Top

Investigational New Drugs

Published in:

01-05-2003

Clinical Trial Design for Target Specific Anticancer Agents

Authors: Ronald Hoekstra, Jaap Verweij, Ferry A.L.M. Eskens

Published in: Investigational New Drugs | Issue 2/2003

Title: Clinical Trial Design for Target Specific Anticancer Agents
Authors: Ronald Hoekstra
Jaap Verweij
Ferry A.L.M. Eskens
Publication date: 01-05-2003
Publisher: Kluwer Academic Publishers
Published in: Investigational New Drugs / Issue 2/2003
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1023/A:1023581731443

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2003

Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology

Noninvasive Methods to Study Drug Distribution

Mechanistic Models for Myelosuppression

Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience

Toxicity Patterns of Cytotoxic Drugs

Introduction: Role of Modeling and Simulation in Clinical Development of Anticancer Agents

Keynote webinar | Spotlight on antibody–drug conjugates in cancer